newsfilter
← Latest News
Business Wire·

Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™

Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial evaluatin